AstraZeneca, Pfizer have similar blood clot cases, also nearly equal to unvaccinated
If a patient exhibits any sign of malady while participating in a major vaccine trial, even if the incident is part of their list of chronic ails, would somebody likely make a note of the event? Is that why the close study of AstraZeneca (AZ) trials shows incidences of rare blood clotting? And to the point, is thromboembolism and the Oxford–AstraZeneca COVID-19 vaccine a side-effect or purely a coincidence? There is still no connection say numerous scientists.
Yet another study by Barcelona’s IDIAP Jordi Gol institute, suggests that rates of venous thromboembolism, a co-occurring deep vein thrombosis and pulmonary embolism, were only slightly higher in people who had received either the AstraZeneca or Pfizer/BioNTech vaccines than the same events occurring in the unvaccinated population and the vaccinated.
The AstraZenica, Johnson and Johnson and the Sputnik V vaccines are each viral vector vaccines. According to the CDC, “Viral vector vaccines use a modified version of a different virus (the vector) to deliver important instructions to our cells.” According to available real world data, these three vaccines are extremely effective, say experts.
by Micheal John
Note: The author of this article has been fully vaccinated (2 X AstraZenica jabs) and like all of FPMag’s editorial staff, contributors and most readers, urge all persons to get vaccinated against COVID-19 and wear an N-95 respirator when away from home or when caring for an ill person at home. We do, and all are COVID-free.
Pharmacy Times and The Lancet report that AstraZeneca research to the end of April suggests that unvaccinated and vaccinated populations experience similar incidence of clotting events.
Today Pharmacy Times is reporting that, “thrombocytopenia syndrome (TTS), a rare clotting disorder, following a second dose of AstraZeneca’s COVID-19 vaccine (Vaxzevria) are comparable to the rate observed in the unvaccinated population.”
The Pharmacy Times cites a published Lancet report, “Very rare thrombosis with thrombocytopenia after second AZD1222 dose: a global safety database analysis.”
“At data cutoff, 13 cases of TTS were identified after the second AZD1222 dose, occurring 1–13 days post-vaccination (appendix p 1; no cases were observed outside the 14-day window). The reported events included eight individuals with pulmonary embolism, co-occurring with cerebral venous sinus thrombosis (CVST) in two individuals; one individual with CVST occurring alone; one individual with deep vein thrombosis; one individual with thrombotic stroke; and two individuals with unspecified embolisms. The 13 vaccinees reporting TTS were aged 45–85 years (one age unknown); eight were female (a lower proportion than in initial TTS reports.” Citing Lancet Report
Is the Oxford AstraZenica vaccine getting a bad rap? Authorities have only ever said that there might be a link between the AZ vaccine and clotting. Perhaps that was premature?
Medical history was available for 11 vaccinees of the thirteen TTS cases in the AZ study , says the Lancet report which is written by AstraZeneca scientists.
One patient apparently had a previous pulmonary embolism, another had previously experienced actual thrombocytopenia; three of these patients had cancer; and one had COVID-19 which is infamous for creating thrombotic events, says the report.
Other pharmacology details were available for seven vaccinees and that data included cancer treatments; antihypertensive pharmaceuticals; antithrombotic medications; and statins (cholesterol control), notes the scientist authors of the report.
Note: Any reader who reads these findings and has questions or thoughts about stopping or changing their medication regime should check with their doctor first.
“Thromboembolism and the Pfizer or Oxford–AstraZeneca COVID-19 vaccines: is it a side-effect or a coincidence?”
That is the question yet another Lancet report examined.
“The matter of these various blood clots is becoming more closely studied and some scientists are now wondering if these thrombotic events may in fact be related to an existing small community of persons who have a predisposition toward low platelets and concomitant clotting events, regardless of vaccines,” says Dr. Fred Harris, a biostatistician and infectious disease researcher in Singapore.
“What is more clear,” Dr. Harris adds, “is that statistical real-world evidence used for recent data studies unequivocally determine that no vaccine has posed risks that even remotely outweigh the risk of not getting vaccinated.”
“When making decisions on the use of drugs based on pharmacovigilance, it is important to take into account the natural incidence of illnesses, such as venous thromboembolisms, that might be interpreted as serious adverse events. Here, based on pre-pandemic incidence rates from the entire Danish population, we report that the number of venous thromboembolisms reported in relation to the Oxford–AstraZeneca COVID-19 vaccine does not seem to be increased beyond the expected incidence rate.” Citing The Lancet.
Have a listen if you wish: Interesting ABC Podcast interview of Liz Chapman, President of AstraZeneca in Australia, recorded before the story broke on the recent reports.